Gardiquimod NEW
| Price | $40 | $64 | $147 |
| Package | 5mg | 10mg | 25mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-02 |
Product Details
| Product Name: Gardiquimod | CAS No.: 1020412-43-4 |
| Purity: 99.68% | Supply Ability: 10g |
| Release date: 2026/06/02 |
Product Introduction
Bioactivity
| Name | Gardiquimod |
| Description | Gardiquimod could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells. Gardiquimod is an imidazoquinoline analog and is a TLR7/8 agonist. When used at concentrations below 10?μM, Gardiquimod specifically activates TLR7. |
| In vitro | Administration of 6-60?μM Gardiquimod obviously inhibits HIV-1 reverse transcriptase cDNA synthesis[1]. |
| In vivo | Gardiquimod (1 mg/kg per mouse; i.p.; daily for 7 days) in combination with Dendritic cells (DCs) enhance the anti-tumor effects of NK cells[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween-80+45% Saline : 2 mg/mL (6.38 mM), Sonication is recommended. 10% DMSO+90% Saline : 4.55 mg/mL (14.52 mM), Solution. DMSO : 45.4 mg/mL (144.86 mM), Sonication is recommended. DMF : 18 mg/mL (57.43 mM), Sonication is recommended. |
| Keywords | Toll-like Receptor (TLR) | TLR8 | TLR7 | peripheral | PBMCs | mononuclear | macrophages | liver | Inhibitor | inhibit | Human immunodeficiency virus | HIVProtease | HIV-1 | HIV Protease | HIV | HepG2 | Gardiquimod | cells | carcinoma | blood |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Emtricitabine | Dolutegravir intermediate-1 | Dimethyl fumarate | Hydroxychloroquine | Lamivudine | Benzyl alcohol | Valproic Acid | (-)-Epigallocatechin Gallate | Decanedioic acid | Dextran sulfate sodium salt (MW 5000) |
| Related Compound Libraries | Bioactive Compound Library | Anti-Alzheimer's Disease Compound Library | Membrane Protein-targeted Compound Library | HIF-1 Signaling Pathway Compound Library | Pyroptosis Compound Library | Antioxidant Compound Library | Anti-Viral Compound Library | Immuno-Oncology Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Infection Compound Library | Human Metabolite Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $49.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-04-20 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY